Rituximab Maintenance Therapy After Autologous Stem Cell Transplantation: Final Analysis of the CORAL Trial
08:59 Share

In this podcast, results of a randomized phase III clinical trial evaluating the use of Rituximab maintenance therapy following autologous stem cell transplantation in patients with relapsed diffuse large B cell lymphoma are summarized. The results demonstrate that Rituximab maintenance therapy does not result in improved event free or overall survival in this patient population.